Purchase Order HT941025PE009
- Not listed
- This federal contract award is for the procurement of GeneXpert Infinity 48S molecular diagnostic systems and associated supplies by the Defense Health Agency. The $487,039.20 firm fixed-price purchase order was awarded to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract has an ultimate completion date of January 13, 2027 and does not have a set-aside designation. Cepheid is an original equipment manufacturer and prime...
- The U.S. Department of Defense's Defense Health Agency has awarded a firm-fixed-price purchase order contract to Cepheid, a for-profit manufacturer of molecular diagnostic solutions, for services related to Cepheid's GeneXpert DX Systems in the Department of Pathology. The contract, valued at $326,745.25, has an ultimate completion date of September 10, 2025. Cepheid, the prime contractor, is not designated as a set-aside. The company has a history of providing diagnostic testing equipment,...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a delivery order valued at $2,471.70 by the Defense Department's Medical Supply Chain organization on July 18, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price delivery order carries no set-aside designation and represents procurement of diagnostic equipment, reagents, or testing services from Cepheid's core product portfolio, which includes GeneXpert...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract is valued at $5,440.00 and has an ultimate completion date of February 18, 2025. The contract is for the provision of Cepheid's GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services to support the detection of infectious diseases such as COVID-19,...
- The Defense Health Agency has awarded a firm-fixed-price purchase order to Cepheid, a for-profit manufacturer of molecular diagnostic solutions, for a GeneXpert IV Service Agreement plus four option years. The contract, valued at $36,197.21, will provide GeneXpert diagnostic equipment, reagents, consumables, and maintenance services to support clinical testing programs for the agency. Cepheid is the prime contractor and original equipment manufacturer, and the contract does not have a...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract, valued at $7,700.00, is for the provision of the company's GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services to support the detection of infectious diseases such as COVID-19, influenza, respiratory syncytial virus (RSV),...
- This is a $7,875.20 firm fixed-price delivery order contract awarded by the Defense Logistics Agency to Cepheid, a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract is for the provision of GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services to support the medical supply chain. The contract has an ultimate completion date of July 15, 2025 and was awarded on June 30, 2025. Cepheid holds several...
- This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain, a defense agency, to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract, valued at $9,078.60, is for the delivery of Cepheid's GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services. The contract has an ultimate completion date of May 23, 2025 and was awarded on May 16, 2025. Cepheid holds several...
- This firm fixed-price purchase order contract, valued at $628,495.80, was awarded by the Defense Health Agency to Cepheid Inc., a for-profit manufacturer of molecular diagnostic solutions based in Sunnyvale, California. The contract provides Cepheid's GeneXpert diagnostic systems, molecular reagents, test kits, and associated maintenance services for detecting infectious diseases such as COVID-19, influenza, respiratory syncytial virus (RSV), Methicillin-resistant Staphylococcus aureus (MRSA),...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency to Cepheid, a for-profit manufacturer of molecular diagnostic solutions. The contract, valued at $199,744.50, is for a standard service agreement for Cepheid's GeneXpert system. The contract has an ultimate completion date of December 10, 2026. Cepheid is the prime contractor and there is no set-aside designation for this award. Cepheid has previously received numerous federal contract and grant awards from agencies...
The Defense Health Agency awarded a $118,080 firm fixed-price purchase order to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic systems, for one Cepheid GeneXpert 16x16 diagnostic instrument (Serial Number 842173) and associated computer equipment. The contract, awarded on July 18, 2025, carries an ultimate completion date of August 4, 2025, and involves no set-aside designation. The GeneXpert platform is a widely-utilized point-of-care molecular diagnostic system designed for rapid detection of infectious diseases and other clinical conditions, and this acquisition supports the Defense Health Agency's operational diagnostic capabilities. Cepheid has established itself as a significant federal contractor in molecular diagnostics, holding multiple indefinite delivery vehicle contracts with the Department of Veterans Affairs valued at over $35 million and maintaining ongoing relationships with the Defense Logistics Agency and Indian Health Service. The company's federal portfolio predominantly focuses on delivering diagnostic equipment, reagents, and testing services for detecting conditions including COVID-19, influenza, respiratory syncytial virus, methicillin-resistant Staphylococcus aureus, and other infectious diseases. This purchase order represents a discrete equipment acquisition consistent with Cepheid's broader role as a provider of molecular diagnostic solutions across federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $118.1k | 7/18/25 |